Jintai Technology

Jintech is an Artificial Intelligence (AI) and robotics-driven innovative R&D platform company.Founded in 2015 by three MIT post-doctoral physicists, Jintech is dedicated to enabling digital and intelligent innovation in life sciences and new materials.

Company Overview

• company identification: QuantumPharm Inc. (Stock Code: 2228.HK)
• Established:: 2015
• creatorShuhao Wen (Chairman, Ph.D. in Physical Chemistry, Chinese Academy of Sciences), Jian Ma (CEO, Ph.D. in Physics, Zhejiang University), Lipeng Lai (Chief Innovation Officer, Dual Degree in Physics and Mathematics, Peking University, Ph.D. in Physics, University of Chicago)
• Type of company: Innovative R&D Platform Inc.
• Headquarters location: Shenzhen, China
• Main business: Provide innovative R&D technologies, services and products for the global biomedical, chemical, new energy and new material industries.

Business areas and technology platforms

Jintech has a wide range of business areas covering a variety of industries, including biomedicine, chemicals, new energy and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing and large-scale experimental robot clusters, the company has built a strong technology platform to provide innovative R&D solutions for global customers.

• Drug Discovery Platform: Jintech has ID4 intelligent drug discovery platform and XupremAb antibody R&D platform to provide end-to-end small molecule drug and large molecule drug discovery solutions for the pharmaceutical and biotech industries.
• Intelligent Automation Platform: The company's intelligent automation tools, such as the XmartChem Workstation and ChemPlus Robot, enable high-throughput, flexible chemical synthesis processes that improve R&D efficiency and success.

Main products and services

• Drug Discovery Solutions: Jintech utilizes AI and robotics to provide the pharmaceutical and biotech industries with a full chain of drug discovery solutions from target validation, seedling compound identification, lead compound generation to preclinical candidate recommendation.
• Intelligent Automation Solutions: The company provides intelligent automated chemical synthesis services, including reaction condition screening, synthetic methodology research and catalyst research, and supports high-throughput processing of various solid samples.
• New Energy and New Materials R&D Services: Jintech also provides R&D services for high-tech materials for the new energy and new materials industry, including order-oriented R&D services in the fields of chalcogenide, supramolecules, lithium-ion batteries, cathode materials, and carbon and silicon materials.

Partners and Achievements

Since its inception, Jintech has established partnerships with more than 100 biotechnology and pharmaceutical companies and research institutions worldwide, including international pharmaceutical giants such as Pfizer, Eli Lilly, Johnson & Johnson, and Merck. The company's partners cover a wide range of industries including pharmaceuticals, biotechnology, agrotechnology, energy and new chemicals.

During the global outbreak triggered by the New Coronavirus, Jintech successfully confirmed the drug-optimal crystal structure of Paxlovid in just 6 weeks using a combination of intelligent algorithm prediction and experimental validation. This breakthrough paved the way for the subsequent development and production of the drug, and Paxlovid became the world's first FDA-approved COVID-19 small molecule drug.

Developments and Future Prospects

• ListingJintech was listed in Hong Kong on June 13, 2024 as the "first company under HKEx Rule 18C" and was included in the Hang Seng Composite Index and entered into the Hong Kong Stock Connect in September.
• Strategic cooperation: In August 2024, Jintai Technology and GCL Group formally signed a five-year strategic cooperation agreement at the GCL Energy Center in Suzhou. Under the agreement, GCL will pay Jintech an estimated R&D fee of approximately US$135 million (approximately RMB 1 billion) in installments in accordance with the project's R&D progress. The two parties will work together to build a customized large model + automation platform in the materials field, and promote industrial intelligence and paradigm upgrading of AI-enabled R&D in the new energy industry.
• future outlook: Jintech will continue to plough into the field of artificial intelligence and robot-driven innovation and research and development, and continuously expand its business fields and technology platforms to provide more efficient, accurate and customized innovation and research and development solutions for its global customers. Meanwhile, the Company will also strengthen strategic cooperation with its partners to jointly promote the innovation and development of related industries.

In summary, Jintech is an innovative research and development platform company driven by artificial intelligence and robotics with strong technological strength and a wide range of business areas. In the future, with the continuous progress of technology and market expansion, Jintech is expected to achieve more significant achievements and breakthroughs in related fields.